Explore Business Standard
Don’t miss the latest developments in business and finance.
Dr Reddy's Laboratories Limited
Dr Reddy's Laboratories on Wednesday reported a 77 per cent increase in its consolidated net profit at Rs 1,247 crore in the third quarter ended December 31, 2022. The drug firm had reported a net profit of Rs 706 crore in the October-December period of the previous fiscal. Revenue from operations rose to Rs 6,770 crore during the period under review as against Rs 5,320 crore in the year-ago period, Dr Reddy's Laboratories said in a regulatory filing.
Dr Reddy's Laboratories on Thursday said all claims against it in the antitrust litigation filed in the US, related to a prescription medicine Revlimid, used in treatment of multiple myeloma have been dismissed. In a regulatory filing, the company said on December 22, 2022 and December 27, 2022, the plaintiffs voluntarily dismissed Dr Reddy's Laboratories Ltd and Dr Reddy's Laboratories, Inc. respectively, from the case. "All claims against the company in the litigation have now been dismissed," Dr Reddy's said. Last month the company had stated that it was among several generic pharmaceutical companies, including Celgene and Bristol Myers Squibb, against which an antitrust litigation has been filed in the District of New Jersey, USA. The complaint had asserted "claims under federal and state antitrust law and other state laws alleging that defendants improperly restrained competition and maintained a shared monopoly in the sale of brand and generic Revlimid in the United States."
Dr Reddy's Laboratories Ltd on Friday said its consolidated profit after tax (PAT) for the quarter ended September 30, 2022 was up by 12 per cent at Rs 1,112.80 crore as against Rs 992 crore in the same quarter a year ago. Revenues during the quarter under discussion were up by nine per cent to Rs 6,305.70 crore compared to Rs 5,215.40 crore in the first quarter of FY '22. Commenting on the results, Co-Chairman and MD, G V Prasad said, "We are pleased with the strong financial performance in the current quarter, driven by the launch of Lenalidomide capsules in the US market. Our focus is to build a robust pipeline with products that improve affordability and access to patients globally. We continue to progress well in our productivity, innovation and sustainability agenda.
The World Economic Forum on Tuesday announced the addition of 11 factories and industrial sites, including three from India, to its Global Lighthouse Network. From India, the additions are pharma major Cipla's Indore facility, Dr Reddy's Laboratories' Hyderabad facility and the Mondelez facility in Sri City. The Global Lighthouse Network is a community of over 100 manufacturers that are showing leadership in applying Fourth Industrial Revolution technologies such as artificial intelligence, 3D-printing and big data analytics. The WEF further said four lighthouse members with outstanding environmental footprint reductions have been given an additional designation of Sustainability Lighthouses. These four include Unilever's Dapada facility in India. The WEF said that amid warnings of a global recession, energy price hikes and disrupted supply chains, the lighthouse factories offer business leaders and policymakers examples of how the manufacturing sector can stay competitive and ...
Dr Reddy's Laboratories Ltd on Monday said Life Insurance Corporation of India has increased its stake to 7.7 per cent in the pharmaceutical firm through purchase of 33.86 lakh shares from open market over a period of time. Life Insurance Corporation of India (LIC) earlier held around 5.65 per cent stake in the company, Dr Reddy's Laboratories (DRL) said in a regulatory filing. Between June 15, 2022 and September 30, 2022 LIC purchased 33,86,486 shares of DRL, aggregating 2.034 per cent stake from the open market, it added. Subsequently, LIC's holding in the company stands at 7.7 per cent, it added.
Dr Reddy's Laboratories Ltd on Thursday said the US health regulator has issued Form 483 with two observations after inspecting its manufacturing facility located at Srikakulam in Andhra Pradesh. As per USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The US Food and Drug Administration (USFDA) completed a pre-approval inspection at the company's formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh on Thursday, Dr Reddy's said in a regulatory filing. The inspection was conducted from June 30, 2022 to July 7, 2022. "We have been issued a Form 483 with two observations, which we will address within the stipulated timeline," the company added.
JB Chemicals & Pharmaceuticals on Thursday said its board has approved a proposal to acquire four paediatric brands from Dr Reddy's Laboratories for about Rs 98 crore. The company's board at its meeting held on June 29, has considered and approved the acquisition of a portfolio of brands, for use sales within India, from Dr Reddy's Laboratories, the drug maker said in a regulatory filing. The company has inked a pact with Dr Reddy's Laboratories to acquire four of its brands -- Z&D, Pedicloryl, Pecef and Ezinapi -- for the India market, it added. All four brands are focused on the paediatric segment in the country with a total covered market size of Rs 1,800 crore as per IQVIA data, JB Chemicals & Pharmaceuticals said. The combined sales of these brands stood at around Rs 33 crore for FY 2021-22, it added. The acquisition, which will be funded primarily through long-term debt, will be completed in the next few working days, the drug firm stated.